Obesity
Obesity
Addressing Obesity
For over 20 years, Schaeffer researchers have examined obesity’s consequences for government budgets, including Medicare and Social Security, the impact it has on individuals’ health outcomes, and the value of new interventions and treatments.
Related Topics
Top Stories View All
News
GLP-1 Prescriptions for New Mothers Have Increased Sharply
Featured Experts: Sih-Ting Cai
In The News View All
CalMatters
Ward discusses tension between GLP-1 long-term savings and near-term insurer costs
Featured Experts: Alison Sexton Ward
BBC
Ward interviewed about substantial drops in GLP-1 prices
Featured Experts: Alison Sexton Ward
Medscape
Peters interviewed about how new GLP-1 guidelines and price reductions will affect patients
Featured Experts: Anne Peters
NPR
Joyce interviewed about White House deal lowering prices on anti-obesity medications
Featured Experts: Geoffrey Joyce
CNBC
Lakdawalla discusses how White House obesity deal will broaden access
Featured Experts: Darius Lakdawalla
Featured White Paper
Benefits of Medicare Coverage for Weight Loss Drugs
The cumulative social benefits from Medicare coverage for new obesity treatments over the next 10 years would reach almost $1 trillion, or roughly $100 billion per year.
Experts: Alison Sexton Ward, Bryan Tysinger, PhuongGiang Nguyen, Dana Goldman, Darius Lakdawalla
Scholar Testimony
Testimony on Incentivizing Chronic Disease Prevention and Treatment
Rebalancing the healthcare system to favor prevention and cures can potentially reduce the long-term burden of obesity and other chronic diseases, Senior Scholar Anne Peters testified before the House Ways and Means health subcommittee.
Read the Testimony
